Newsletter Signup x
New, more effective and less toxic drugs are needed for children who have relapsed acute lymphoblastic leukaemia (ALL) or are at high risk of relapse. Unfortunately, developing new cancer drugs usually costs millions of pounds and takes many years to reach patients. Rather than create new drugs from scratch, Dr Julie Irving and her team aim to bypass these cost and time constraints by screening ALL cells for potential drug targets and matching them against already existing drugs that are used for other types of cancer but could be repurposed to use against ALL.
Optimising the use of repurposed drugs to improve the treatment of children with ALL
Prof. Julie Irving
Newcastle University
Newcastle upon Tyne, NE2 4HH
1 February 2021
33 months
£213,259.00
Back to school crafts kit
To recognise Childhood Cancer Awareness Month this September 2022, Children with Cancer UK has partnered up with Made By
Read morePatient Story – Sienna
Sienna was diagnosed with acute myeloid leukaemia in December 2022, one day after her 7th birthday. Her mum, Kayleigh,
Read moreEarly diagnosis of classical Hodgkin lymphoma
Although the cure rate is high for Hodgkin lymphoma, it’s easily mistaken for other diseases, like glandular fever. Finding
Read more